{
  "DOI": "10.1007/s00439-017-1792-9",
  "ISSN": [
    "0340-6717",
    "1432-1203"
  ],
  "URL": "http://dx.doi.org/10.1007/s00439-017-1792-9",
  "alternative-id": [
    "1792"
  ],
  "author": [
    {
      "affiliation": [],
      "family": "Munkley",
      "given": "Jennifer",
      "sequence": "first"
    },
    {
      "affiliation": [],
      "family": "Livermore",
      "given": "Karen",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Rajan",
      "given": "Prabhakar",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Elliott",
      "given": "David J.",
      "sequence": "additional"
    }
  ],
  "container-title": [
    "Human Genetics"
  ],
  "content-domain": {
    "crossmark-restriction": false,
    "domain": [
      "link.springer.com"
    ]
  },
  "created": {
    "date-parts": [
      [
        2017,
        4,
        5
      ]
    ],
    "date-time": "2017-04-05T15:47:49Z",
    "timestamp": 1491407269000
  },
  "deposited": {
    "date-parts": [
      [
        2017,
        9,
        16
      ]
    ],
    "date-time": "2017-09-16T14:58:37Z",
    "timestamp": 1505573917000
  },
  "funder": [
    {
      "DOI": "10.13039/501100000771",
      "award": [
        "PG12-34",
        "S13-020"
      ],
      "doi-asserted-by": "publisher",
      "name": "Prostate Cancer UK"
    }
  ],
  "indexed": {
    "date-parts": [
      [
        2024,
        4,
        20
      ]
    ],
    "date-time": "2024-04-20T19:18:22Z",
    "timestamp": 1713640702534
  },
  "is-referenced-by-count": 43,
  "issn-type": [
    {
      "type": "print",
      "value": "0340-6717"
    },
    {
      "type": "electronic",
      "value": "1432-1203"
    }
  ],
  "issue": "9",
  "issued": {
    "date-parts": [
      [
        2017,
        4,
        5
      ]
    ]
  },
  "journal-issue": {
    "issue": "9",
    "published-print": {
      "date-parts": [
        [
          2017,
          9
        ]
      ]
    }
  },
  "language": "en",
  "license": [
    {
      "URL": "http://creativecommons.org/licenses/by/4.0",
      "content-version": "unspecified",
      "delay-in-days": 0,
      "start": {
        "date-parts": [
          [
            2017,
            4,
            5
          ]
        ],
        "date-time": "2017-04-05T00:00:00Z",
        "timestamp": 1491350400000
      }
    }
  ],
  "link": [
    {
      "URL": "http://link.springer.com/article/10.1007/s00439-017-1792-9/fulltext.html",
      "content-type": "text/html",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "http://link.springer.com/content/pdf/10.1007/s00439-017-1792-9.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "http://link.springer.com/content/pdf/10.1007/s00439-017-1792-9.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "similarity-checking"
    }
  ],
  "member": "297",
  "page": "1143-1154",
  "prefix": "10.1007",
  "published": {
    "date-parts": [
      [
        2017,
        4,
        5
      ]
    ]
  },
  "published-online": {
    "date-parts": [
      [
        2017,
        4,
        5
      ]
    ]
  },
  "published-print": {
    "date-parts": [
      [
        2017,
        9
      ]
    ]
  },
  "publisher": "Springer Science and Business Media LLC",
  "reference": [
    {
      "DOI": "10.1089/nat.2016.0657",
      "author": "A Aartsma-Rus",
      "doi-asserted-by": "publisher",
      "first-page": "1",
      "journal-title": "Nucleic Acid Ther",
      "key": "1792_CR1",
      "unstructured": "Aartsma-Rus A, Krieg AM (2017) FDA approves eteplirsen for Duchenne muscular dystrophy: the next chapter in the Eteplirsen Saga. Nucleic Acid Ther 27:1–3. doi:\n                        10.1089/nat.2016.0657",
      "volume": "27",
      "year": "2017"
    },
    {
      "DOI": "10.1038/onc.2015.109",
      "author": "P Adamo",
      "doi-asserted-by": "publisher",
      "first-page": "403",
      "journal-title": "Oncogene",
      "key": "1792_CR2",
      "unstructured": "Adamo P, Ladomery MR (2016) The oncogene ERG: a key factor in prostate cancer. Oncogene 35:403–414. doi:\n                        10.1038/onc.2015.109",
      "volume": "35",
      "year": "2016"
    },
    {
      "DOI": "10.1371/journal.pgen.1006318",
      "author": "E Allemand",
      "doi-asserted-by": "publisher",
      "first-page": "e1006318",
      "journal-title": "PLoS Genet",
      "key": "1792_CR3",
      "unstructured": "Allemand E, Myers MP, Garcia-Bernardo J, Harel-Bellan A, Krainer AR, Muchardt C (2016) A broad set of chromatin factors influences splicing. PLoS Genet 12:e1006318. doi:\n                        10.1371/journal.pgen.1006318",
      "volume": "12",
      "year": "2016"
    },
    {
      "DOI": "10.1016/j.ccr.2011.10.016",
      "author": "EM Amin",
      "doi-asserted-by": "publisher",
      "first-page": "768",
      "journal-title": "Cancer Cell",
      "key": "1792_CR4",
      "unstructured": "Amin EM, Oltean S, Hua J, Gammons MV, Hamdollah-Zadeh M, Welsh GI, Cheung MK, Ni L, Kase S, Rennel ES, Symonds KE, Nowak DG, Royer-Pokora B, Saleem MA, Hagiwara M, Schumacher VA, Harper SJ, Hinton DR, Bates DO, Ladomery MR (2011) WT1 mutants reveal SRPK1 to be a downstream angiogenesis target by altering VEGF splicing. Cancer Cell 20:768–780. doi:\n                        10.1016/j.ccr.2011.10.016",
      "volume": "20",
      "year": "2011"
    },
    {
      "DOI": "10.1016/j.eururo.2014.11.020",
      "author": "AU Anand",
      "doi-asserted-by": "publisher",
      "first-page": "349",
      "journal-title": "Eur Urol",
      "key": "1792_CR5",
      "unstructured": "Anand AU, Bjartell A (2015) Re: AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. Eur Urol 67:349–350. doi:\n                        10.1016/j.eururo.2014.11.020",
      "volume": "67",
      "year": "2015"
    },
    {
      "DOI": "10.1056/NEJMoa1315815",
      "author": "ES Antonarakis",
      "doi-asserted-by": "publisher",
      "first-page": "1028",
      "journal-title": "N Engl J Med",
      "key": "1792_CR6",
      "unstructured": "Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Fedor HL, Lotan TL, Zheng Q, De Marzo AM, Isaacs JT, Isaacs WB, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J (2014) AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 371:1028–1038. doi:\n                        10.1056/NEJMoa1315815",
      "volume": "371",
      "year": "2014"
    },
    {
      "DOI": "10.1001/jamaoncol.2015.1341",
      "author": "ES Antonarakis",
      "doi-asserted-by": "publisher",
      "first-page": "582",
      "journal-title": "JAMA Oncol",
      "key": "1792_CR7",
      "unstructured": "Antonarakis ES, Lu C, Luber B, Wang H, Chen Y, Nakazawa M, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J (2015) Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer. JAMA Oncol 1:582–591. doi:\n                        10.1001/jamaoncol.2015.1341",
      "volume": "1",
      "year": "2015"
    },
    {
      "DOI": "10.1038/ncomms5760",
      "author": "A Best",
      "doi-asserted-by": "publisher",
      "first-page": "4760",
      "journal-title": "Nat Commun",
      "key": "1792_CR8",
      "unstructured": "Best A, James K, Dalgliesh C, Hong E, Kheirolahi-Kouhestani M, Curk T, Xu Y, Danilenko M, Hussain R, Keavney B, Wipat A, Klinck R, Cowell IG, Cheong Lee K, Austin CA, Venables JP, Chabot B, Santibanez Koref M, Tyson-Capper A, Elliott DJ (2014) Human Tra2 proteins jointly control a CHEK1 splicing switch among alternative and constitutive target exons. Nat Commun 5:4760. doi:\n                        10.1038/ncomms5760",
      "volume": "5",
      "year": "2014"
    },
    {
      "DOI": "10.1007/s11705-015-1540-4",
      "author": "A Best",
      "doi-asserted-by": "publisher",
      "first-page": "186",
      "journal-title": "Front Chem Sci Eng",
      "key": "1792_CR9",
      "unstructured": "Best A, James K, Hysenaj G, Tyson-Capper A, Elliott DJ (2016) Transformer2 proteins protect breast cancer cells from accumulating replication stress by ensuring productive splicing of checkpoint kinase 1. Front Chem Sci Eng 10:186–195. doi:\n                        10.1007/s11705-015-1540-4",
      "volume": "10",
      "year": "2016"
    },
    {
      "DOI": "10.1002/embr.201338241",
      "author": "P Bielli",
      "doi-asserted-by": "publisher",
      "first-page": "419",
      "journal-title": "EMBO Rep",
      "key": "1792_CR10",
      "unstructured": "Bielli P, Busa R, Di Stasi SM, Munoz MJ, Botti F, Kornblihtt AR, Sette C (2014) The transcription factor FBI-1 inhibits SAM68-mediated BCL-X alternative splicing and apoptosis. EMBO Rep 15:419–427. doi:\n                        10.1002/embr.201338241",
      "volume": "15",
      "year": "2014"
    },
    {
      "DOI": "10.1002/path.4846",
      "author": "N Bullock",
      "doi-asserted-by": "publisher",
      "journal-title": "J Pathol",
      "key": "1792_CR11",
      "unstructured": "Bullock N, Oltean S (2016) The many faces of SRPK1. J Pathol. doi:\n                        10.1002/path.4846",
      "year": "2016"
    },
    {
      "DOI": "10.1136/jclinpath-2015-203125",
      "author": "N Bullock",
      "doi-asserted-by": "publisher",
      "first-page": "171",
      "journal-title": "J Clin Pathol",
      "key": "1792_CR12",
      "unstructured": "Bullock N, Potts J, Simpkin AJ, Koupparis A, Harper SJ, Oxley J, Oltean S (2016) Serine-arginine protein kinase 1 (SRPK1), a determinant of angiogenesis, is upregulated in prostate cancer and correlates with disease stage and invasion. J Clin Pathol 69:171–175. doi:\n                        10.1136/jclinpath-2015-203125",
      "volume": "69",
      "year": "2016"
    },
    {
      "DOI": "10.1038/sj.onc.1210224",
      "author": "R Busa",
      "doi-asserted-by": "publisher",
      "first-page": "4372",
      "journal-title": "Oncogene",
      "key": "1792_CR13",
      "unstructured": "Busa R, Paronetto MP, Farini D, Pierantozzi E, Botti F, Angelini DF, Attisani F, Vespasiani G, Sette C (2007) The RNA-binding protein Sam68 contributes to proliferation and survival of human prostate cancer cells. Oncogene 26:4372–4382. doi:\n                        10.1038/sj.onc.1210224",
      "volume": "26",
      "year": "2007"
    },
    {
      "DOI": "10.18632/oncotarget.1802",
      "author": "B Cao",
      "doi-asserted-by": "publisher",
      "first-page": "1646",
      "journal-title": "Oncotarget",
      "key": "1792_CR14",
      "unstructured": "Cao B, Qi Y, Zhang G, Xu D, Zhan Y, Alvarez X, Guo Z, Fu X, Plymate SR, Sartor O, Zhang H, Dong Y (2014) Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy. Oncotarget 5:1646–1656. doi:\n                        10.18632/oncotarget.1802",
      "volume": "5",
      "year": "2014"
    },
    {
      "DOI": "10.1038/onc.2013.360",
      "author": "M Cappellari",
      "doi-asserted-by": "publisher",
      "first-page": "3794",
      "journal-title": "Oncogene",
      "key": "1792_CR15",
      "unstructured": "Cappellari M, Bielli P, Paronetto MP, Ciccosanti F, Fimia GM, Saarikettu J, Silvennoinen O, Sette C (2014) The transcriptional co-activator SND1 is a novel regulator of alternative splicing in prostate cancer cells. Oncogene 33:3794–3802. doi:\n                        10.1038/onc.2013.360",
      "volume": "33",
      "year": "2014"
    },
    {
      "DOI": "10.1158/0008-5472.CAN-08-0932",
      "author": "EL Clark",
      "doi-asserted-by": "publisher",
      "first-page": "7938",
      "journal-title": "Cancer Res",
      "key": "1792_CR16",
      "unstructured": "Clark EL, Coulson A, Dalgliesh C, Rajan P, Nicol SM, Fleming S, Heer R, Gaughan L, Leung HY, Elliott DJ, Fuller-Pace FV, Robson CN (2008) The RNA helicase p68 is a novel androgen receptor coactivator involved in splicing and is overexpressed in prostate cancer. Cancer Res 68:7938–7946. doi:\n                        10.1158/0008-5472.CAN-08-0932",
      "volume": "68",
      "year": "2008"
    },
    {
      "author": "Y Diao",
      "first-page": "6967",
      "journal-title": "Int J Clin Exp Pathol",
      "key": "1792_CR17",
      "unstructured": "Diao Y, Wu D, Dai Z, Kang H, Wang Z, Wang X (2015) Prognostic value of transformer 2beta expression in prostate cancer. Int J Clin Exp Pathol 8:6967–6973",
      "volume": "8",
      "year": "2015"
    },
    {
      "DOI": "10.1038/nature11233",
      "author": "S Djebali",
      "doi-asserted-by": "publisher",
      "first-page": "101",
      "journal-title": "Nature",
      "key": "1792_CR18",
      "unstructured": "Djebali S, Davis CA, Merkel A, Dobin A, Lassmann T, Mortazavi A, Tanzer A, Lagarde J, Lin W, Schlesinger F, Xue C, Marinov GK, Khatun J, Williams BA, Zaleski C, Rozowsky J, Roder M, Kokocinski F, Abdelhamid RF, Alioto T, Antoshechkin I, Baer MT, Bar NS, Batut P, Bell K, Bell I, Chakrabortty S, Chen X, Chrast J, Curado J, Derrien T, Drenkow J, Dumais E, Dumais J, Duttagupta R, Falconnet E, Fastuca M, Fejes-Toth K, Ferreira P, Foissac S, Fullwood MJ, Gao H, Gonzalez D, Gordon A, Gunawardena H, Howald C, Jha S, Johnson R, Kapranov P, King B, Kingswood C, Luo OJ, Park E, Persaud K, Preall JB, Ribeca P, Risk B, Robyr D, Sammeth M, Schaffer L, See LH, Shahab A, Skancke J, Suzuki AM, Takahashi H, Tilgner H, Trout D, Walters N, Wang H, Wrobel J, Yu Y, Ruan X, Hayashizaki Y, Harrow J, Gerstein M, Hubbard T, Reymond A, Antonarakis SE, Hannon G, Giddings MC, Ruan Y, Wold B, Carninci P, Guigo R, Gingeras TR (2012) Landscape of transcription in human cells. Nature 489:101–108. doi:\n                        10.1038/nature11233",
      "volume": "489",
      "year": "2012"
    },
    {
      "DOI": "10.1038/nmeth.2227",
      "author": "VC Evans",
      "doi-asserted-by": "publisher",
      "first-page": "1207",
      "journal-title": "Nat Methods",
      "key": "1792_CR19",
      "unstructured": "Evans VC, Barker G, Heesom KJ, Fan J, Bessant C, Matthews DA (2012) De novo derivation of proteomes from transcriptomes for transcript and protein identification. Nat Methods 9:1207–1211. doi:\n                        10.1038/nmeth.2227",
      "volume": "9",
      "year": "2012"
    },
    {
      "DOI": "10.1038/ncomms10355",
      "author": "M Feracci",
      "doi-asserted-by": "publisher",
      "first-page": "10355",
      "journal-title": "Nat Commun",
      "key": "1792_CR20",
      "unstructured": "Feracci M, Foot JN, Grellscheid SN, Danilenko M, Stehle R, Gonchar O, Kang HS, Dalgliesh C, Meyer NH, Liu Y, Lahat A, Sattler M, Eperon IC, Elliott DJ, Dominguez C (2016) Structural basis of RNA recognition and dimerization by the STAR proteins T-STAR and Sam68. Nat Commun 7:10355. doi:\n                        10.1038/ncomms10355",
      "volume": "7",
      "year": "2016"
    },
    {
      "DOI": "10.1158/0008-5472.CAN-15-2186",
      "author": "R Ferraldeschi",
      "doi-asserted-by": "publisher",
      "first-page": "2731",
      "journal-title": "Cancer Res",
      "key": "1792_CR21",
      "unstructured": "Ferraldeschi R, Welti J, Powers MV, Yuan W, Smyth T, Seed G, Riisnaes R, Hedayat S, Wang H, Crespo M, Nava Rodrigues D, Figueiredo I, Miranda S, Carreira S, Lyons JF, Sharp S, Plymate SR, Attard G, Wallis N, Workman P, de Bono JS (2016) Second-generation HSP90 inhibitor Onalespib blocks mRNA splicing of androgen receptor variant 7 in prostate cancer cells. Cancer Res 76:2731–2742. doi:\n                        10.1158/0008-5472.CAN-15-2186",
      "volume": "76",
      "year": "2016"
    },
    {
      "DOI": "10.18632/oncotarget.975",
      "author": "JL Gillis",
      "doi-asserted-by": "publisher",
      "first-page": "691",
      "journal-title": "Oncotarget",
      "key": "1792_CR22",
      "unstructured": "Gillis JL, Selth LA, Centenera MM, Townley SL, Sun S, Plymate SR, Tilley WD, Butler LM (2013) Constitutively-active androgen receptor variants function independently of the HSP90 chaperone but do not confer resistance to HSP90 inhibitors. Oncotarget 4:691–704. doi:\n                        10.18632/oncotarget.975",
      "volume": "4",
      "year": "2013"
    },
    {
      "DOI": "10.1016/S0022-5347(17)59889-4",
      "author": "DF Gleason",
      "doi-asserted-by": "crossref",
      "first-page": "58",
      "journal-title": "J Urol",
      "key": "1792_CR23",
      "unstructured": "Gleason DF, Mellinger GT (1974) Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 111:58–64",
      "volume": "111",
      "year": "1974"
    },
    {
      "DOI": "10.1042/BST20120026",
      "author": "RM Hagen",
      "doi-asserted-by": "publisher",
      "first-page": "870",
      "journal-title": "Biochem Soc Trans",
      "key": "1792_CR24",
      "unstructured": "Hagen RM, Ladomery MR (2012) Role of splice variants in the metastatic progression of prostate cancer. Biochem Soc Trans 40:870–874. doi:\n                        10.1042/BST20120026",
      "volume": "40",
      "year": "2012"
    },
    {
      "DOI": "10.1309/AJCPH88QHXARISUP",
      "author": "RM Hagen",
      "doi-asserted-by": "publisher",
      "first-page": "533",
      "journal-title": "Am J Clin Pathol",
      "key": "1792_CR25",
      "unstructured": "Hagen RM, Adamo P, Karamat S, Oxley J, Aning JJ, Gillatt D, Persad R, Ladomery MR, Rhodes A (2014) Quantitative analysis of ERG expression and its splice isoforms in formalin-fixed, paraffin-embedded prostate cancer samples: association with seminal vesicle invasion and biochemical recurrence. Am J Clin Pathol 142:533–540. doi:\n                        10.1309/AJCPH88QHXARISUP",
      "volume": "142",
      "year": "2014"
    },
    {
      "DOI": "10.1016/j.cell.2011.02.013",
      "author": "D Hanahan",
      "doi-asserted-by": "publisher",
      "first-page": "646",
      "journal-title": "Cell",
      "key": "1792_CR26",
      "unstructured": "Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674. doi:\n                        10.1016/j.cell.2011.02.013",
      "volume": "144",
      "year": "2011"
    },
    {
      "DOI": "10.1038/ncomms13668",
      "author": "C Henzler",
      "doi-asserted-by": "publisher",
      "first-page": "13668",
      "journal-title": "Nat Commun",
      "key": "1792_CR27",
      "unstructured": "Henzler C, Li Y, Yang R, McBride T, Ho Y, Sprenger C, Liu G, Coleman I, Lakely B, Li R, Ma S, Landman SR, Kumar V, Hwang TH, Raj GV, Higano CS, Morrissey C, Nelson PS, Plymate SR, Dehm SM (2016) Truncation and constitutive activation of the androgen receptor by diverse genomic rearrangements in prostate cancer. Nat Commun 7:13668. doi:\n                        10.1038/ncomms13668",
      "volume": "7",
      "year": "2016"
    },
    {
      "DOI": "10.1158/0008-5472.CAN-11-3892",
      "author": "R Hu",
      "doi-asserted-by": "publisher",
      "first-page": "3457",
      "journal-title": "Cancer Res",
      "key": "1792_CR28",
      "unstructured": "Hu R, Lu C, Mostaghel EA, Yegnasubramanian S, Gurel M, Tannahill C, Edwards J, Isaacs WB, Nelson PS, Bluemn E, Plymate SR, Luo J (2012) Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Res 72:3457–3462. doi:\n                        10.1158/0008-5472.CAN-11-3892",
      "volume": "72",
      "year": "2012"
    },
    {
      "DOI": "10.1038/srep40957",
      "author": "D Jones",
      "doi-asserted-by": "publisher",
      "first-page": "40957",
      "journal-title": "Sci Rep",
      "key": "1792_CR29",
      "unstructured": "Jones D, Noble M, Wedge SR, Robson CN, Gaughan L (2017) Aurora A regulates expression of AR-V7 in models of castrate resistant prostate cancer. Sci Rep 7:40957. doi:\n                        10.1038/srep40957",
      "volume": "7",
      "year": "2017"
    },
    {
      "DOI": "10.1038/nsmb0106-5",
      "author": "AR Kornblihtt",
      "doi-asserted-by": "publisher",
      "first-page": "5",
      "journal-title": "Nat Struct Mol Biol",
      "key": "1792_CR30",
      "unstructured": "Kornblihtt AR (2006) Chromatin, transcript elongation and alternative splicing. Nat Struct Mol Biol 13:5–7. doi:\n                        10.1038/nsmb0106-5",
      "volume": "13",
      "year": "2006"
    },
    {
      "DOI": "10.1155/2013/463786",
      "author": "M Ladomery",
      "doi-asserted-by": "publisher",
      "first-page": "463786",
      "journal-title": "Int J Cell Biol",
      "key": "1792_CR31",
      "unstructured": "Ladomery M (2013) Aberrant alternative splicing is another hallmark of cancer. Int J Cell Biol 2013:463786. doi:\n                        10.1155/2013/463786",
      "volume": "2013",
      "year": "2013"
    },
    {
      "DOI": "10.1038/onc.2011.637",
      "author": "Y Li",
      "doi-asserted-by": "publisher",
      "first-page": "4759",
      "journal-title": "Oncogene",
      "key": "1792_CR32",
      "unstructured": "Li Y, Hwang TH, Oseth LA, Hauge A, Vessella RL, Schmechel SC, Hirsch B, Beckman KB, Silverstein KA, Dehm SM (2012) AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression. Oncogene 31:4759–4767. doi:\n                        10.1038/onc.2011.637",
      "volume": "31",
      "year": "2012"
    },
    {
      "DOI": "10.1016/j.eururo.2016.04.028",
      "author": "Y Li",
      "doi-asserted-by": "publisher",
      "journal-title": "Eur Urol",
      "key": "1792_CR33",
      "unstructured": "Li Y, Donmez N, Sahinalp C, Xie N, Wang Y, Xue H, Mo F, Beltran H, Gleave M, Collins C, Dong X (2016) SRRM4 drives neuroendocrine transdifferentiation of prostate adenocarcinoma under androgen receptor pathway inhibition. Eur Urol. doi:\n                        10.1016/j.eururo.2016.04.028",
      "year": "2016"
    },
    {
      "DOI": "10.1593/neo.13784",
      "author": "G Liu",
      "doi-asserted-by": "crossref",
      "first-page": "1009",
      "journal-title": "Neoplasia",
      "key": "1792_CR34",
      "unstructured": "Liu G, Sprenger C, Sun S, Epilepsia KS, Haugk K, Zhang X, Coleman I, Nelson PS, Plymate S (2013) AR variant ARv567es induces carcinogenesis in a novel transgenic mouse model of prostate cancer. Neoplasia 15:1009–1017",
      "volume": "15",
      "year": "2013"
    },
    {
      "DOI": "10.1158/1078-0432.CCR-13-3296",
      "author": "C Liu",
      "doi-asserted-by": "publisher",
      "first-page": "3198",
      "journal-title": "Clin Cancer Res",
      "key": "1792_CR35",
      "unstructured": "Liu C, Lou W, Zhu Y, Nadiminty N, Schwartz CT, Evans CP, Gao AC (2014a) Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer. Clin Cancer Res 20:3198–3210. doi:\n                        10.1158/1078-0432.CCR-13-3296",
      "volume": "20",
      "year": "2014"
    },
    {
      "DOI": "10.1038/onc.2013.284",
      "author": "LL Liu",
      "doi-asserted-by": "publisher",
      "first-page": "3140",
      "journal-title": "Oncogene",
      "key": "1792_CR36",
      "unstructured": "Liu LL, Xie N, Sun S, Plymate S, Mostaghel E, Dong X (2014b) Mechanisms of the androgen receptor splicing in prostate cancer cells. Oncogene 33:3140–3150. doi:\n                        10.1038/onc.2013.284",
      "volume": "33",
      "year": "2014"
    },
    {
      "DOI": "10.18632/oncotarget.2672",
      "author": "G Liu",
      "doi-asserted-by": "publisher",
      "first-page": "288",
      "journal-title": "Oncotarget",
      "key": "1792_CR37",
      "unstructured": "Liu G, Sprenger C, Wu PJ, Sun S, Uo T, Haugk K, Epilepsia KS, Plymate S (2015) MED1 mediates androgen receptor splice variant induced gene expression in the absence of ligand. Oncotarget 6:288–304. doi:\n                        10.18632/oncotarget.2672",
      "volume": "6",
      "year": "2015"
    },
    {
      "DOI": "10.18632/oncotarget.8493",
      "author": "C Liu",
      "doi-asserted-by": "publisher",
      "first-page": "32210",
      "journal-title": "Oncotarget",
      "key": "1792_CR38",
      "unstructured": "Liu C, Armstrong C, Zhu Y, Lou W, Gao AC (2016) Niclosamide enhances abiraterone treatment via inhibition of androgen receptor variants in castration resistant prostate cancer. Oncotarget 7:32210–32220. doi:\n                        10.18632/oncotarget.8493",
      "volume": "7",
      "year": "2016"
    },
    {
      "DOI": "10.3934/molsci.2016.2.280",
      "author": "KE Livermore",
      "doi-asserted-by": "crossref",
      "first-page": "280",
      "journal-title": "AIMS Mol Sci",
      "key": "1792_CR39",
      "unstructured": "Livermore KE (2016) Androgen receptor and prostate cancer. AIMS Mol Sci 3:280–299",
      "volume": "3",
      "year": "2016"
    },
    {
      "DOI": "10.3978/j.issn.2223-4683.2013.09.08",
      "author": "C Lu",
      "doi-asserted-by": "publisher",
      "first-page": "178",
      "journal-title": "Transl Androl Urol",
      "key": "1792_CR40",
      "unstructured": "Lu C, Luo J (2013) Decoding the androgen receptor splice variants. Transl Androl Urol 2:178–186. doi:\n                        10.3978/j.issn.2223-4683.2013.09.08",
      "volume": "2",
      "year": "2013"
    },
    {
      "DOI": "10.1038/nrurol.2015.13",
      "author": "J Lu",
      "doi-asserted-by": "publisher",
      "first-page": "137",
      "journal-title": "Nat Rev Urol",
      "key": "1792_CR41",
      "unstructured": "Lu J, Van der Steen T, Tindall DJ (2015) Are androgen receptor variants a substitute for the full-length receptor? Nat Rev Urol 12:137–144. doi:\n                        10.1038/nrurol.2015.13",
      "volume": "12",
      "year": "2015"
    },
    {
      "DOI": "10.1016/j.phrs.2016.03.013",
      "author": "A Mavrou",
      "doi-asserted-by": "publisher",
      "first-page": "276",
      "journal-title": "Pharmacol Res",
      "key": "1792_CR42",
      "unstructured": "Mavrou A, Oltean S (2016) SRPK1 inhibition in prostate cancer: a novel anti-angiogenic treatment through modulation of VEGF alternative splicing. Pharmacol Res 107:276–281. doi:\n                        10.1016/j.phrs.2016.03.013",
      "volume": "107",
      "year": "2016"
    },
    {
      "DOI": "10.1038/onc.2014.360",
      "author": "A Mavrou",
      "doi-asserted-by": "publisher",
      "first-page": "4311",
      "journal-title": "Oncogene",
      "key": "1792_CR43",
      "unstructured": "Mavrou A, Brakspear K, Hamdollah-Zadeh M, Damodaran G, Babaei-Jadidi R, Oxley J, Gillatt DA, Ladomery MR, Harper SJ, Bates DO, Oltean S (2015) Serine-arginine protein kinase 1 (SRPK1) inhibition as a potential novel targeted therapeutic strategy in prostate cancer. Oncogene 34:4311–4319. doi:\n                        10.1038/onc.2014.360",
      "volume": "34",
      "year": "2015"
    },
    {
      "DOI": "10.1016/S0022-5347(17)63039-8",
      "author": "GT Mellinger",
      "doi-asserted-by": "crossref",
      "first-page": "331",
      "journal-title": "J Urol",
      "key": "1792_CR44",
      "unstructured": "Mellinger GT, Gleason D, Bailar J 3rd (1967) The histology and prognosis of prostatic cancer. J Urol 97:331–337",
      "volume": "97",
      "year": "1967"
    },
    {
      "DOI": "10.1038/nrc3678",
      "author": "IG Mills",
      "doi-asserted-by": "publisher",
      "first-page": "187",
      "journal-title": "Nat Rev Cancer",
      "key": "1792_CR45",
      "unstructured": "Mills IG (2014) Maintaining and reprogramming genomic androgen receptor activity in prostate cancer. Nat Rev Cancer 14:187–198. doi:\n                        10.1038/nrc3678",
      "volume": "14",
      "year": "2014"
    },
    {
      "DOI": "10.1126/science.aab0917",
      "author": "DT Miyamoto",
      "doi-asserted-by": "publisher",
      "first-page": "1351",
      "journal-title": "Science",
      "key": "1792_CR46",
      "unstructured": "Miyamoto DT, Zheng Y, Wittner BS, Lee RJ, Zhu H, Broderick KT, Desai R, Fox DB, Brannigan BW, Trautwein J, Arora KS, Desai N, Dahl DM, Sequist LV, Smith MR, Kapur R, Wu CL, Shioda T, Ramaswamy S, Ting DT, Toner M, Maheswaran S, Haber DA (2015) RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance. Science 349:1351–1356. doi:\n                        10.1126/science.aab0917",
      "volume": "349",
      "year": "2015"
    },
    {
      "DOI": "10.3390/ijms17030275",
      "author": "J Munkley",
      "doi-asserted-by": "publisher",
      "first-page": "275",
      "journal-title": "Int J Mol Sci",
      "key": "1792_CR47",
      "unstructured": "Munkley J (2016) The role of sialyl-Tn in cancer. Int J Mol Sci 17:275. doi:\n                        10.3390/ijms17030275",
      "volume": "17",
      "year": "2016"
    },
    {
      "DOI": "10.18632/oncotarget.1405",
      "author": "J Munkley",
      "doi-asserted-by": "publisher",
      "first-page": "131",
      "journal-title": "Oncotarget",
      "key": "1792_CR48",
      "unstructured": "Munkley J, Rajan P, Lafferty NP, Dalgliesh C, Jackson RM, Robson CN, Leung HY, Elliott DJ (2014) A novel androgen-regulated isoform of the TSC2 tumour suppressor gene increases cell proliferation. Oncotarget 5:131–139. doi:\n                        10.18632/oncotarget.1405",
      "volume": "5",
      "year": "2014"
    },
    {
      "DOI": "10.18632/oncotarget.6024",
      "author": "J Munkley",
      "doi-asserted-by": "publisher",
      "first-page": "34358",
      "journal-title": "Oncotarget",
      "key": "1792_CR49",
      "unstructured": "Munkley J, Oltean S, Vodak D, Wilson BT, Livermore KE, Zhou Y, Star E, Floros VI, Johannessen B, Knight B, McCullagh P, McGrath J, Crundwell M, Skotheim RI, Robson CN, Leung HY, Harries LW, Rajan P, Mills IG, Elliott DJ (2015) The androgen receptor controls expression of the cancer-associated sTn antigen and cell adhesion through induction of ST6GalNAc1 in prostate cancer. Oncotarget 6:34358–34374. doi:\n                        10.18632/oncotarget.6024",
      "volume": "6",
      "year": "2015"
    },
    {
      "DOI": "10.1016/j.ebiom.2016.04.018",
      "author": "J Munkley",
      "doi-asserted-by": "publisher",
      "first-page": "103",
      "journal-title": "EBioMedicine",
      "key": "1792_CR50",
      "unstructured": "Munkley J, Vodak D, Livermore KE, James K, Wilson BT, Knight B, McCullagh P, McGrath J, Crundwell M, Harries LW, Leung HY, Robson CN, Mills IG, Rajan P, Elliott DJ (2016) Glycosylation is an androgen-regulated process essential for prostate cancer cell viability. EBioMedicine 8:103–116. doi:\n                        10.1016/j.ebiom.2016.04.018",
      "volume": "8",
      "year": "2016"
    },
    {
      "DOI": "10.1158/1535-7163.MCT-14-1057",
      "author": "N Nadiminty",
      "doi-asserted-by": "publisher",
      "first-page": "1884",
      "journal-title": "Mol Cancer Ther",
      "key": "1792_CR51",
      "unstructured": "Nadiminty N, Tummala R, Liu C, Lou W, Evans CP, Gao AC (2015) NF-kappaB2/p52:c-Myc:hnRNPA1 pathway regulates expression of androgen receptor splice variants and enzalutamide sensitivity in prostate cancer. Mol Cancer Ther 14:1884–1895. doi:\n                        10.1158/1535-7163.MCT-14-1057",
      "volume": "14",
      "year": "2015"
    },
    {
      "DOI": "10.1007/s12672-014-0190-1",
      "author": "M Nakazawa",
      "doi-asserted-by": "publisher",
      "first-page": "265",
      "journal-title": "Horm Cancer",
      "key": "1792_CR52",
      "unstructured": "Nakazawa M, Antonarakis ES, Luo J (2014) Androgen receptor splice variants in the era of enzalutamide and abiraterone. Horm Cancer 5:265–273. doi:\n                        10.1007/s12672-014-0190-1",
      "volume": "5",
      "year": "2014"
    },
    {
      "DOI": "10.1038/nmeth.3144",
      "author": "AI Nesvizhskii",
      "doi-asserted-by": "publisher",
      "first-page": "1114",
      "journal-title": "Nat Methods",
      "key": "1792_CR53",
      "unstructured": "Nesvizhskii AI (2014) Proteogenomics: concepts, applications and computational strategies. Nat Methods 11:1114–1125. doi:\n                        10.1038/nmeth.3144",
      "volume": "11",
      "year": "2014"
    },
    {
      "DOI": "10.1038/onc.2013.533",
      "author": "S Oltean",
      "doi-asserted-by": "publisher",
      "first-page": "5311",
      "journal-title": "Oncogene",
      "key": "1792_CR54",
      "unstructured": "Oltean S, Bates DO (2014) Hallmarks of alternative splicing in cancer. Oncogene 33:5311–5318. doi:\n                        10.1038/onc.2013.533",
      "volume": "33",
      "year": "2014"
    },
    {
      "DOI": "10.1016/j.eururo.2015.07.007",
      "author": "W Onstenk",
      "doi-asserted-by": "publisher",
      "first-page": "939",
      "journal-title": "Eur Urol",
      "key": "1792_CR55",
      "unstructured": "Onstenk W, Sieuwerts AM, Kraan J, Van M, Nieuweboer AJ, Mathijssen RH, Hamberg P, Meulenbeld HJ, De Laere B, Dirix LY, van Soest RJ, Lolkema MP, Martens JW, van Weerden WM, Jenster GW, Foekens JA, de Wit R, Sleijfer S (2015) Efficacy of cabazitaxel in castration-resistant prostate cancer is independent of the presence of AR-V7 in circulating tumor cells. Eur Urol 68:939–945. doi:\n                        10.1016/j.eururo.2015.07.007",
      "volume": "68",
      "year": "2015"
    },
    {
      "DOI": "10.1016/j.urolonc.2015.12.011",
      "author": "GS Palapattu",
      "doi-asserted-by": "publisher",
      "journal-title": "Urol Oncol.",
      "key": "1792_CR56",
      "unstructured": "Palapattu GS (2016) Commentary on “AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.” Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, Lotan TL, Zheng Q, De Marzo AM, Isaacs JT, Isaacs WB, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J, Division of Urologic Oncology, Department of Urology, University of Michigan, MI. N Engl J Med 2014; 371(11):1028–38. Urol Oncol. doi:\n                        10.1016/j.urolonc.2015.12.011",
      "year": "2016"
    },
    {
      "DOI": "10.1002/path.2324",
      "author": "P Rajan",
      "doi-asserted-by": "publisher",
      "first-page": "67",
      "journal-title": "J Pathol",
      "key": "1792_CR57",
      "unstructured": "Rajan P, Gaughan L, Dalgliesh C, El-Sherif A, Robson CN, Leung HY, Elliott DJ (2008) The RNA-binding and adaptor protein Sam68 modulates signal-dependent splicing and transcriptional activity of the androgen receptor. J Pathol 215:67–77. doi:\n                        10.1002/path.2324",
      "volume": "215",
      "year": "2008"
    },
    {
      "DOI": "10.1186/1471-2121-10-82",
      "author": "P Rajan",
      "doi-asserted-by": "publisher",
      "first-page": "82",
      "journal-title": "BMC Cell Biol",
      "key": "1792_CR58",
      "unstructured": "Rajan P, Dalgliesh C, Bourgeois CF, Heiner M, Emami K, Clark EL, Bindereif A, Stevenin J, Robson CN, Leung HY, Elliott DJ (2009a) Proteomic identification of heterogeneous nuclear ribonucleoprotein L as a novel component of SLM/Sam68 nuclear bodies. BMC Cell Biol 10:82. doi:\n                        10.1186/1471-2121-10-82",
      "volume": "10",
      "year": "2009"
    },
    {
      "DOI": "10.1038/nrurol.2009.125",
      "author": "P Rajan",
      "doi-asserted-by": "publisher",
      "first-page": "454",
      "journal-title": "Nat Rev Urol",
      "key": "1792_CR59",
      "unstructured": "Rajan P, Elliott DJ, Robson CN, Leung HY (2009b) Alternative splicing and biological heterogeneity in prostate cancer. Nat Rev Urol 6:454–460. doi:\n                        10.1038/nrurol.2009.125",
      "volume": "6",
      "year": "2009"
    },
    {
      "DOI": "10.1371/journal.pone.0029088",
      "author": "P Rajan",
      "doi-asserted-by": "publisher",
      "first-page": "e29088",
      "journal-title": "PLoS ONE",
      "key": "1792_CR60",
      "unstructured": "Rajan P, Dalgliesh C, Carling PJ, Buist T, Zhang C, Grellscheid SN, Armstrong K, Stockley J, Simillion C, Gaughan L, Kalna G, Zhang MQ, Robson CN, Leung HY, Elliott DJ (2011) Identification of novel androgen-regulated pathways and mRNA isoforms through genome-wide exon-specific profiling of the LNCaP transcriptome. PLoS ONE 6:e29088. doi:\n                        10.1371/journal.pone.0029088",
      "volume": "6",
      "year": "2011"
    },
    {
      "DOI": "10.1083/jcb.201207087",
      "author": "F Rigo",
      "doi-asserted-by": "publisher",
      "first-page": "21",
      "journal-title": "J Cell Biol",
      "key": "1792_CR61",
      "unstructured": "Rigo F, Hua Y, Krainer AR, Bennett CF (2012) Antisense-based therapy for the treatment of spinal muscular atrophy. J Cell Biol 199:21–25. doi:\n                        10.1083/jcb.201207087",
      "volume": "199",
      "year": "2012"
    },
    {
      "DOI": "10.1038/528S128a",
      "author": "N Savage",
      "doi-asserted-by": "publisher",
      "first-page": "S128",
      "journal-title": "Nature",
      "key": "1792_CR62",
      "unstructured": "Savage N (2015) Metastasis: resistance fighters. Nature 528:S128–S129. doi:\n                        10.1038/528S128a",
      "volume": "528",
      "year": "2015"
    },
    {
      "DOI": "10.1101/gr.199935.115",
      "author": "E Sebestyen",
      "doi-asserted-by": "publisher",
      "first-page": "732",
      "journal-title": "Genome Res",
      "key": "1792_CR63",
      "unstructured": "Sebestyen E, Singh B, Minana B, Pages A, Mateo F, Pujana MA, Valcarcel J, Eyras E (2016) Large-scale analysis of genome and transcriptome alterations in multiple tumors unveils novel cancer-relevant splicing networks. Genome Res 26:732–744. doi:\n                        10.1101/gr.199935.115",
      "volume": "26",
      "year": "2016"
    },
    {
      "DOI": "10.1155/2013/458727",
      "author": "C Sette",
      "doi-asserted-by": "publisher",
      "first-page": "458727",
      "journal-title": "Int J Cell Biol",
      "key": "1792_CR64",
      "unstructured": "Sette C (2013) Alternative splicing programs in prostate cancer. Int J Cell Biol 2013:458727. doi:\n                        10.1155/2013/458727",
      "volume": "2013",
      "year": "2013"
    },
    {
      "DOI": "10.18632/oncotarget.5585",
      "author": "AA Shafi",
      "doi-asserted-by": "publisher",
      "first-page": "31997",
      "journal-title": "Oncotarget",
      "key": "1792_CR65",
      "unstructured": "Shafi AA, Putluri V, Arnold JM, Tsouko E, Maity S, Roberts JM, Coarfa C, Frigo DE, Putluri N, Sreekumar A, Weigel NL (2015) Differential regulation of metabolic pathways by androgen receptor (AR) and its constitutively active splice variant, AR-V7, in prostate cancer cells. Oncotarget 6:31997–32012. doi:\n                        10.18632/oncotarget.5585",
      "volume": "6",
      "year": "2015"
    },
    {
      "DOI": "10.4161/rna.28800",
      "author": "J Stockley",
      "doi-asserted-by": "crossref",
      "first-page": "755",
      "journal-title": "RNA Biol",
      "key": "1792_CR66",
      "unstructured": "Stockley J, Villasevil ME, Nixon C, Ahmad I, Leung HY, Rajan P (2014) The RNA-binding protein hnRNPA2 regulates beta-catenin protein expression and is overexpressed in prostate cancer. RNA Biol 11:755–765",
      "volume": "11",
      "year": "2014"
    },
    {
      "DOI": "10.1038/srep13426",
      "author": "J Stockley",
      "doi-asserted-by": "publisher",
      "first-page": "13426",
      "journal-title": "Sci Rep",
      "key": "1792_CR67",
      "unstructured": "Stockley J, Markert E, Zhou Y, Robson CN, Elliott DJ, Lindberg J, Leung HY, Rajan P (2015) The RNA-binding protein Sam68 regulates expression and transcription function of the androgen receptor splice variant AR-V7. Sci Rep 5:13426. doi:\n                        10.1038/srep13426",
      "volume": "5",
      "year": "2015"
    },
    {
      "DOI": "10.1016/j.eururo.2015.03.054",
      "author": "M Sun",
      "doi-asserted-by": "publisher",
      "first-page": "162",
      "journal-title": "Eur Urol",
      "key": "1792_CR68",
      "unstructured": "Sun M, Abdollah F (2015) Re: AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer. Eur Urol 68:162–163. doi:\n                        10.1016/j.eururo.2015.03.054",
      "volume": "68",
      "year": "2015"
    },
    {
      "DOI": "10.1074/jbc.M113.492140",
      "author": "F Sun",
      "doi-asserted-by": "publisher",
      "first-page": "1529",
      "journal-title": "J Biol Chem",
      "key": "1792_CR69",
      "unstructured": "Sun F, Chen HG, Li W, Yang X, Wang X, Jiang R, Guo Z, Chen H, Huang J, Borowsky AD, Qiu Y (2014) Androgen receptor splice variant AR3 promotes prostate cancer via modulating expression of autocrine/paracrine factors. J Biol Chem 289:1529–1539. doi:\n                        10.1074/jbc.M113.492140",
      "volume": "289",
      "year": "2014"
    },
    {
      "DOI": "10.1016/j.molcel.2016.02.012",
      "author": "B Sundararaman",
      "doi-asserted-by": "publisher",
      "first-page": "903",
      "journal-title": "Mol Cell",
      "key": "1792_CR70",
      "unstructured": "Sundararaman B, Zhan L, Blue SM, Stanton R, Elkins K, Olson S, Wei X, Van Nostrand EL, Pratt GA, Huelga SC, Smalec BM, Wang X, Hong EL, Davidson JM, Lecuyer E, Graveley BR, Yeo GW (2016) Resources for the comprehensive discovery of functional RNA elements. Mol Cell 61:903–913. doi:\n                        10.1016/j.molcel.2016.02.012",
      "volume": "61",
      "year": "2016"
    },
    {
      "DOI": "10.1016/j.juro.2014.11.066",
      "author": "SS Taneja",
      "doi-asserted-by": "publisher",
      "first-page": "538",
      "journal-title": "J Urol",
      "key": "1792_CR71",
      "unstructured": "Taneja SS (2015) Re: AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. J Urol 193:538. doi:\n                        10.1016/j.juro.2014.11.066",
      "volume": "193",
      "year": "2015"
    },
    {
      "DOI": "10.1158/0008-5472.CAN-13-2876",
      "author": "M Thadani-Mulero",
      "doi-asserted-by": "publisher",
      "first-page": "2270",
      "journal-title": "Cancer Res",
      "key": "1792_CR72",
      "unstructured": "Thadani-Mulero M, Portella L, Sun S, Sung M, Matov A, Vessella RL, Corey E, Nanus DM, Plymate SR, Giannakakou P (2014) Androgen receptor splice variants determine taxane sensitivity in prostate cancer. Cancer Res 74:2270–2282. doi:\n                        10.1158/0008-5472.CAN-13-2876",
      "volume": "74",
      "year": "2014"
    },
    {
      "DOI": "10.1016/j.ajpath.2013.03.011",
      "author": "R Tummala",
      "doi-asserted-by": "publisher",
      "first-page": "288",
      "journal-title": "Am J Pathol",
      "key": "1792_CR73",
      "unstructured": "Tummala R, Nadiminty N, Lou W, Zhu Y, Gandour-Edwards R, Chen HW, Evans CP, Gao AC (2013) Lin28 promotes growth of prostate cancer cells and activates the androgen receptor. Am J Pathol 183:288–295. doi:\n                        10.1016/j.ajpath.2013.03.011",
      "volume": "183",
      "year": "2013"
    },
    {
      "DOI": "10.1002/pros.23134",
      "author": "R Tummala",
      "doi-asserted-by": "publisher",
      "first-page": "445",
      "journal-title": "Prostate",
      "key": "1792_CR74",
      "unstructured": "Tummala R, Nadiminty N, Lou W, Evans CP, Gao AC (2016) Lin28 induces resistance to anti-androgens via promotion of AR splice variant generation. Prostate 76:445–455. doi:\n                        10.1002/pros.23134",
      "volume": "76",
      "year": "2016"
    },
    {
      "DOI": "10.1016/j.eururo.2016.03.049",
      "author": "J Welti",
      "doi-asserted-by": "publisher",
      "journal-title": "Eur Urol",
      "key": "1792_CR75",
      "unstructured": "Welti J, Rodrigues DN, Sharp A, Sun S, Lorente D, Riisnaes R, Figueiredo I, Zafeiriou Z, Rescigno P, de Bono JS, Plymate SR (2016) Analytical validation and clinical qualification of a new immunohistochemical assay for androgen receptor splice variant-7 protein expression in metastatic castration-resistant prostate cancer. Eur Urol. doi:\n                        10.1016/j.eururo.2016.03.049",
      "year": "2016"
    },
    {
      "DOI": "10.1158/1078-0432.CCR-13-1863",
      "author": "Z Yu",
      "doi-asserted-by": "publisher",
      "first-page": "1590",
      "journal-title": "Clin Cancer Res",
      "key": "1792_CR76",
      "unstructured": "Yu Z, Chen S, Sowalsky AG, Voznesensky OS, Mostaghel EA, Nelson PS, Cai C, Balk SP (2014) Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer. Clin Cancer Res 20:1590–1600. doi:\n                        10.1158/1078-0432.CCR-13-1863",
      "volume": "20",
      "year": "2014"
    },
    {
      "DOI": "10.1158/1078-0432.CCR-15-0157",
      "author": "X Zhang",
      "doi-asserted-by": "publisher",
      "first-page": "4698",
      "journal-title": "Clin Cancer Res",
      "key": "1792_CR77",
      "unstructured": "Zhang X, Coleman IM, Brown LG, True LD, Kollath L, Lucas JM, Lam HM, Dumpit R, Corey E, Chery L, Lakely B, Higano CS, Montgomery B, Roudier M, Lange PH, Nelson PS, Vessella RL, Morrissey C (2015) SRRM4 expression and the loss of REST activity may promote the emergence of the neuroendocrine phenotype in castration-resistant prostate cancer. Clin Cancer Res 21:4698–4708. doi:\n                        10.1158/1078-0432.CCR-15-0157",
      "volume": "21",
      "year": "2015"
    }
  ],
  "reference-count": 77,
  "references-count": 77,
  "resource": {
    "primary": {
      "URL": "http://link.springer.com/10.1007/s00439-017-1792-9"
    }
  },
  "score": 0,
  "short-container-title": [
    "Hum Genet"
  ],
  "source": "Crossref",
  "title": [
    "RNA splicing and splicing regulator changes in prostate cancer pathology"
  ],
  "type": "journal-article",
  "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy",
  "volume": "136"
}